Sanofi, Zealand Pharma Announces GetGoal Duo 1 and GetGoal-L Phase III Data on Lixisenatide to be Presented at ADA
Zealand Pharma A/S informs that its partner Sanofi (NYSE: SNY) announced Saturday the presentation of further data from the GetGoal Duo 12 and GetGoal-L3 Phase III studies with lixisenatide, an investigational once-daily GLP-1 agonist discovered by Zealand Pharma and licensed to Sanofi for the treatment of Type 2 diabetes. The data were presented at the ADA's 72th Annual Scientific sessions, taking place on 9 - 12 June 2012 in Philadelphia, Pennsylvania, USA.
The data demonstrate that as add-on to basal insulin plus anti-diabetic agents, lixisenatide significantly reduced blood glucose levels (HbA1c) in patients with Type 2 diabetes; including patients, who were new to insulin therapy, i.e. who had been treated with insulin for only 12 weeks (GetGoal Duo 1), and patients who had already been treated with insulin for an average of 3.1 years (GetGoal-L).
Top-line results from GetGoal Duo 1 and GetGoal-L were announced by Sanofi and Zealand Pharma on 6 December 2011 and on 31 May 2011, respectively, showing that in both studies lixisenatide achieved the primary efficacy endpoint of improved blood glucose levels (HbA1c) with an associated significant reduction in postprandial glucose. Results also showed a significant effect on body weight for lixisenatide compared to placebo.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.